Clinical Trial Update: Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating thiopegfilgrastim to prevent bone marrow suppression during chemoradiotherapy for thoracic neoplasms, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thoracic Neoplasms

Drugs mentioned

• Thiopegfilgrastim (thiopegfilgrastim)

Snippet

Sponsor: Affiliated Hospital of Nantong University | Conditions: Myelosuppression, Thoracic Neoplasms | Phase 2 | Status: RECRUITING